<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04669197</url>
  </required_header>
  <id_info>
    <org_study_id>HCQ NABPLAGEM-NEO 2020</org_study_id>
    <nct_id>NCT04669197</nct_id>
  </id_info>
  <brief_title>Phase II Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydrochloroquine as Treatment in Untreated Pancreas Cancer</brief_title>
  <official_title>A Phase II Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin+ Hydroxychlororoquine as Preoperative Treatment in Patients With Untreated Resectable, Borderline Resectable and Locally Advanced Adenocarcinoma of the Pancreas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HonorHealth Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HonorHealth Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the normalization rate of CA 19-9 of individuals with non-metastatic pancreas&#xD;
      cancer following up to 6 months of neoadjuvant chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Normalization Rate of CA 19-9</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluate the normalization rate of CA 19-9 of individuals with non-metastatic pancreas cancer following up to 6 months of neoadjuvant chemotherapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Resectability Rate</measure>
    <time_frame>6 months to 2 years</time_frame>
    <description>Assess the resectability rate following neoadjuvant chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival Rate</measure>
    <time_frame>2 years</time_frame>
    <description>Assess the 2 year survival from date of study entry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>6 months to 2 years</time_frame>
    <description>Assess the pathologic complete response rate and radiologic response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>6 months to 2 years</time_frame>
    <description>Assess the Grade 3 or Grade 4 related adverse events as assessed by CTCAE Version 5.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Untreated Resectable Pancreatic Adenocarcinoma</condition>
  <condition>Borderline Resectable Pancreatic Adenocarcinoma</condition>
  <condition>Locally Advanced Pancreatic Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydrochloroquine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel protein bound</intervention_name>
    <description>combination therapy</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>combination therapy</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>combination therapy</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>combination therapy</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient has histologically or cytologically confirmed resectable, borderline&#xD;
             resectable, or locally advanced (unresectable) PDAC (based upon Tempero et al 2016)&#xD;
&#xD;
          -  Age ≥ 18 years.&#xD;
&#xD;
          -  If a female patient is of child-bearing potential, she must have a negative serum&#xD;
             pregnancy test (≥β-hCG) documented within 72 hours of the first administration of&#xD;
             study drug&#xD;
&#xD;
          -  If sexually active, the patient and partner must agree to use contraception considered&#xD;
             adequate and appropriate by the Investigator&#xD;
&#xD;
          -  Patient must have received no prior chemotherapy or radiation therapy for PDAC&#xD;
&#xD;
          -  Patients must have normal organ and marrow function&#xD;
&#xD;
          -  Patient has acceptable coagulation status as indicated by an INR ≤ 1.5 x ULN. Patients&#xD;
             on anticoagulation can be included at the discretion of the investigator.&#xD;
&#xD;
          -  Karnofsky Performance Status (KPS) of ≥70%.&#xD;
&#xD;
          -  Have an elevated CA 19-9 (&gt;2X ULN) in the context of normal bilirubin&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient will be excluded from this study if any of the following criteria apply:&#xD;
             Evidence of metastatic disease. No metastatic disease defined as any one or more of&#xD;
             the following; Suspicious lymphadenopathy outside of the standard surgical field (i.e.&#xD;
             aortocaval nodes, distant abdominal nodes) or Radiographic evidence for metastatic&#xD;
             disease in distant organs, peritoneum, or ascites&#xD;
&#xD;
          -  Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic&#xD;
             therapy.&#xD;
&#xD;
          -  Known infection with HIV, hepatitis B, or hepatitis C.&#xD;
&#xD;
          -  Has undergone major surgery, other than diagnostic surgery (i.e.--surgery done to&#xD;
             obtain a biopsy for diagnosis without removal of an organ), within 4 weeks prior to&#xD;
             Day 1 of treatment in this study.&#xD;
&#xD;
          -  History of allergy or hypersensitivity to the study drugs.&#xD;
&#xD;
          -  Serious medical risk factors involving any of the major organ systems such that the&#xD;
             Investigator considers it unsafe for the patient to receive an experimental research&#xD;
             drug.&#xD;
&#xD;
          -  Current, serious, clinically significant cardiac arrhythmias as determined by the&#xD;
             investigator.&#xD;
&#xD;
          -  Patient is unwilling or unable to comply with study procedures.&#xD;
&#xD;
          -  Patient is enrolled in an industry sponsored clinical trial involving treatment with&#xD;
             investigational therapy. Patients enrolled in HonorHealth sponsored research studies&#xD;
             may be eligible to participate as long as their participation in the other research&#xD;
             studies does not confound the data collected for this study.&#xD;
&#xD;
          -  Patient with a history of interstitial lung disease, history of slowly progressive&#xD;
             dyspnea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis,&#xD;
             pulmonary hypersensitivity pneumonitis or multiple allergies.&#xD;
&#xD;
          -  Use of non-FDA approved cannabinoids are prohibited. Total daily usage of up to 40 mg&#xD;
             per day of marinol is acceptable.&#xD;
&#xD;
        Exclusion Criteria for Hydroxychloroquine Expansion Cohort only:&#xD;
&#xD;
          -  Prolonged QTcF &gt; 450 ms for men and &gt; 470 ms for women at Screening. Electrolyte&#xD;
             imbalances (e.g. hypokalemia/hypomagnesemia/hypocalcemia) must be corrected prior to&#xD;
             first dose of hydroxychloroquine.&#xD;
&#xD;
          -  Known second or third degree atrioventricular block.&#xD;
&#xD;
          -  Patient is taking a concomitant medication that has &quot;known&quot; risk of QT prolongation or&#xD;
             torsdades de pointe.&#xD;
&#xD;
          -  Patient has pre-existing retinopathy.&#xD;
&#xD;
          -  Patient has known hypersensitivity to hydroxychloroquine or other 4-aminoquinoline&#xD;
             compounds.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erkut Borazanci, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HonorHealth Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joyce Schaffer</last_name>
    <phone>480-323-1339</phone>
    <phone_ext>Option 2</phone_ext>
    <email>joschaffer@honorhealth.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>HonorHealth Research Institute</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joyce Schaffer, MSN, AOCNS</last_name>
      <phone>480-323-1339</phone>
      <phone_ext>option #2</phone_ext>
      <email>Joyce.Schaffer@HonorHealth.com</email>
    </contact>
    <investigator>
      <last_name>Erkut Borazanci, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 1, 2020</study_first_submitted>
  <study_first_submitted_qc>December 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 16, 2020</study_first_posted>
  <last_update_submitted>December 16, 2020</last_update_submitted>
  <last_update_submitted_qc>December 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

